reference/33002789

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/33002789

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Journal Article\|Research Support, Non-U.S. Gov't
endingPage	3413
issn	1528-0020 0006-4971
issueIdentifier	22
pageRange	3406-3413
publicationName	Blood
startingPage	3406
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_448c3d7a8b95445db230c0de0b6d375a
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_8c485e41acc37667eca30ca80c20af48 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_bcf177961e430f607222697ff32343fa
bibliographicCitation	Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Coutre SE, Benson DM, Peterman S, Cho Y, Webb HK, Johnson DM, Yu AS, Ulrich RG, Godfrey WR, Miller LL, Spurgeon SE. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014 May 29;123(22):3406–13. PMID: 24615776; PMCID: PMC4260978.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3abf417a65d2791112bb879df5c1596a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_25c149f39d99626d4c7616d646ff32cc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4104c9c601c16e369062ec788dd3470d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_207020d8a7634ed1a8ad1126c1d1b1fd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f3c9e6a5aa57d1d34bb056e0d6b5f09c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c4dc471326051c872ab5c950adf0560a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ff71fc31b42c004f8811d7c2139bf204 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_179fd7e0e2c7fb0e5e1f9012b28ed005 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ab7408008e1a24b67eefd8c8ff4902d5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_191f9f901622232de240d4cd0276f4df http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_77d5a5296626f2b201079065cfb6e3b8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_783ac5d823748e942e1c04dd28059cfc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5f8de8441ca8cfda708fd2bc3b6dce1f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b6e7dcc4a16f636fc8e8458b832a8e09 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1ad0c39d25585eb8fc9b8874fec592ff http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_688d645917349aa85e7a45073a9bced5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0c71637cba40fbc8d17679e87de2d741 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cbebc124b5a48259041649e9bab4753c
date	2014-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/24615776 https://pubmed.ncbi.nlm.nih.gov/PMC4260978 https://doi.org/10.1182/blood-2013-11-538546
isPartOf	https://portal.issn.org/resource/ISSN/0006-4971 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1243 https://portal.issn.org/resource/ISSN/1528-0020
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Coutre SE, Benson DM, Peterman S, Cho Y, Webb HK, Johnson DM, Yu AS, Ulrich RG, Godfrey WR, Miller LL, Spurgeon SE: Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014 May 29;123(22):3406-13. doi: 10.1182/blood-2013-11-538546. Epub 2014 Mar 10.
discusses	http://id.nlm.nih.gov/mesh/M000649677 http://id.nlm.nih.gov/mesh/M0018169 http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0592589 http://id.nlm.nih.gov/mesh/M0490629
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D011687Q000627 http://id.nlm.nih.gov/mesh/D000970Q000627 http://id.nlm.nih.gov/mesh/D000081082 http://id.nlm.nih.gov/mesh/D052999Q000627 http://id.nlm.nih.gov/mesh/D008228Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D011687Q000008 http://id.nlm.nih.gov/mesh/D008228Q000175 http://id.nlm.nih.gov/mesh/D008228Q000401 http://id.nlm.nih.gov/mesh/D016879 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D000970Q000493 http://id.nlm.nih.gov/mesh/D052999Q000009 http://id.nlm.nih.gov/mesh/D000970Q000009 http://id.nlm.nih.gov/mesh/D000970Q000008 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D052999Q000493 http://id.nlm.nih.gov/mesh/D011687Q000493 http://id.nlm.nih.gov/mesh/D011687Q000009 http://id.nlm.nih.gov/mesh/D060787 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D052999Q000008 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D000368
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7732 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8593 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6873 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9408 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7660 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7453 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8390 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10698 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_78edc8e186d4ca89a5d99640d0f188ad http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11625818

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID310264996

Total number of triples: 86.